GILEAD SCIENCES, INC. 8K

Gilead Sciences reported strong second quarter 2026 revenue growth but a large net loss driven by major acquired IPR&D charges tied to recent acquisitions, updated 2026 guidance, completed significant M&A and financings, and announced multiple key regulatory, clinical, and commercial developments across its portfolio.

On August 4, 2026, Gilead Sciences, Inc. reported its second quarter 2026 results, highlighting a 10% year-over-year increase in total revenues to $7.8 billion and 10% growth in base product sales (excluding Veklury) to $7.6 billion driven by strong HIV, Trodelvy and Livdelzi sales, but posting a GAAP diluted loss per share of $(8.45) and non-GAAP diluted loss per share of $(6.75) primarily due to $11.2 billion of acquired in-process R&D charges and related tax effects from the acquisitions of Arcellx, Tubulis and Ouro Medicines, as well as an IPR&D impairment. The company’s cash and marketable securities fell to $3.2 billion from $10.6 billion at year-end 2025 due to $11.3 billion of acquisition-related cash outflows, debt repayments, dividends and share repurchases, partially offset by new debt issuance and strong operating cash flow. Gilead updated its 2026 guidance, modestly raising full-year product sales and base business sales expectations while reducing projected Veklury sales and widening GAAP losses per share, and narrowing non-GAAP loss per share expectations. The company also reported significant clinical and regulatory milestones, including multiple FDA approvals (for Trodelvy in first-line metastatic triple-negative breast cancer and Hepcludex in HDV), positive Phase 3 data in HIV and liver disease, acceptance of a supplemental NDA for once-weekly oral Yeztugo for HIV PrEP, and the discontinuation of the EVOKE-03 Phase 3 trial in lung cancer. Additionally, Gilead completed the acquisitions of Tubulis and Ouro Medicines, entered or expanded collaborations (including with Lakefront and Merck), issued $3.0 billion of senior notes and borrowed $1.1 billion under a term loan, renewed a five-year collaboration with the World Health Organization, and declared a $0.82 per share quarterly dividend payable September 29, 2026.

Filing Facts

CIK

882095

Ticker

GILD

Form

8K

Source Type

fda

Accession

0000882095-26-000028

Alert Tier

9